Phytopharm plc (PYM: London Stock Exchange) (“Phytopharm” or the “Company”) today issues
its Interim Management Statement (“IMS”) which relates to the period from 1 October 2009 to 11
February 2010 and contains information up to the date of publication of this IMS.
Highlights for the period
· Phytopharm announced headline results from the successful completion of two key studies
in October 2009:
o A non-clinical efficacy study in the gold-standard, non-clinical model of Parkinson’s
disease (PD).
The oral administration of Cogane™ over 18 weeks significantly reduced
parkinsonian disability by 43% in non-human primates, which will be
clinically significant if repeated in PD patients.
A statistically significant reduction in parkinsonian symptoms was reached
after 9 weeks of administration of Cogane™, and the effect was still
increasing at the end of the study at week 18. This study was funded by a
$1.16 million grant from the Michael J. Fox Foundation for Parkinson’s
disease.
o A Phase Ib safety, tolerability and pharmacokinetic clinical study with Cogane™.
Cogane™ was shown to be safe and generally well tolerated in both healthy
volunteers and PD patients over the 28 day study period.
At steady state, plasma levels in PD patients taking Cogane™ at a dose of
150 mg/day reached levels associated with efficacy in the non-human primate
study and other non-clinical disease models of PD.
· £24.1 million net raised in December 2009 through a Placing and Open Offer.
· Appointment of Mr Roger Hickling as Research and Development Director and Phytopharm
Board Director in January 2010.
Outlook
Following the successful Placing and Open Offer in December 2009 Phytopharm is executing the
agreed strategy. The principal focus is progression of product candidates for treating
neurodegenerative diseases in our clinical and pre-clinical pipeline.
The top priority is Cogane™ for the treatment of Parkinson’s disease:
· Phytopharm has initiated the necessary preparatory and regulatory activities with a CRO for
the planned Cogane™ Phase II proof of concept and dose range finding clinical study to
demonstrate efficacy and determine the optimal dose of Cogane™ in PD patients. A letter of
intent has been signed with the CRO & the contractual discussions are proceeding.
· In parallel, product development work on Cogane™ is being undertaken to improve the
commercial & technical viability of its manufacture/drug formulation so that the information
is available for a rapid progression into the clinical trials.
· The intent is to begin the Cogane™ study with patients with PD in the USA in mid 2010.
The study will then be extended into several other countries and is due for completion in
early 2012.
Development of Cogane™, Myogane™ and other Sapogenin compounds for identified neurodegenerative
disease opportunities will be considered as data from pre-clinical studies is available
during 2010, considering commercial opportunities.
Phytopharm continues to maintain strong relationships with key disease specific charities and
pursue other sources of non-dilutive funding. These contacts will be progressed as will applications
for further non-dilutive funding, as appropriate. Decisions on the current applications for nondilutive
funding are not expected until later in Q2, 2010.
Expenditure on the Group’s residual functional food programmes remains limited and efforts are
mainly focussed on pursuing new partnering arrangements.
As indicated at the time of the Open Offer in December 2009, the Board intends to appoint a new
CEO. The search is underway and progressing as planned. An announcement will be made when
the selection process is satisfactorily completed.
Phytopharm plc
Phytopharm is focused on the development of its pharmaceutical programmes and has a residual
portfolio of functional foods. The Company’s products are developed predominantly from
medicinal plants, thereby reducing the development risk of a product. The Company has focused its
research and development activities on areas of high unmet health needs to deliver cures and relieve
suffering for longer healthier lives.
As a virtual company, the Company’s business model is centred on a lean cash burn with all
laboratory, manufacturing and clinical work outsourced to specialists, while core competencies such
as strategy and management are maintained in-house. Close collaboration with charitable
organisations enhances the Company’s interaction with scientists and clinicians, who lead and
develop expert opinion. Cash grants from them accelerate the Company’s development
programmes, thereby increasing their value.
Phytopharm is listed on the Official List of the London Stock Exchange. Further information on
Phytopharm is available from the Company’s website www.phytopharm.com
